Roche Launches Cobas Eplex RP3 In CE Markets, Featuring First Flexible Syndromic Testing With Up To 5 Customisable Panels For Local Needs

ROCHE HOLDINGS AG +4.53% Pre
ROCHE HOLDINGS AG +0.46% Pre
ROCHE HOLDINGS AG -4.54% Pre

ROCHE HOLDINGS AG

RHHBF

411.00

411.00

+4.53%

0.00% Pre

ROCHE HOLDINGS AG

RHHBY

50.31

50.51

+0.46%

+0.40% Pre

ROCHE HOLDINGS AG

RHHVF

381.84

381.84

-4.54%

0.00% Pre
  • The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample.
  • Rapid results enable doctors to make fast, confident and critical treatment decisions that are vital for high-risk patients.
  • Designed for the cobas eplex system, the test is easy to use and available around the clock, helping hospitals manage surges in respiratory cases.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.